Asthma remains a significant global health concern, with a notable burden in India. Despite advancements in asthma treatment, a subset of patients continues to experience uncontrolled symptoms and frequent exacerbations, leading to increased morbidity, mortality, and healthcare costs. Biologics have emerged as a promising addition to standard therapies, offering targeted, precision treatment for severe asthma patients. This comprehensive review explores the role of biologics in managing severe asthma, focusing on their target site, clinical efficacy, safety profiles, and their future prospects. Various biologics, including anti-immunoglobulin E, anti-interleukin (IL)-5, anti-IL-4/IL-13, and anti-IL-17, have demonstrated efficacy in controlling symptoms and reducing exacerbations in different patients according to their profile. The review also highlights the potential of novel biologics targeting alarmins and emerging predictive biomarkers for personalized medicine in asthma management. The safety profile of biologics appears favorable, with the most common adverse effects being mild injection site reactions. However, careful patient assessment and regular monitoring are essential to identify and manage potential risks. While biologic therapies have shown remarkable effectiveness in managing severe asthma, their accessibility and cost-effectiveness remain challenges in some regions. Overall, biologics represent a paradigm shift in the treatment of severe asthma, offering targeted and personalized therapies that significantly enhance disease control and improve patient outcomes. This review also emphasizes the importance of continued research and development in the field, indicating a promising future for biologics in asthma management.
Rout et al. (Tue,) studied this question.